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Abstract
Background: To investigate whether serum chitinase-3-like 1 protein (YKL-40) is associated with disease activity in
anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Methods: ELISA was performed in serum samples from AAV patients who were enrolled in our prospective
observational cohort to estimate levels of YKL-40. Birmingham vasculitis activity score (BVAS) (version 3), five factor
score (FFS), and short form-36 (SF-36), as well as clinical and laboratory data were collected. Kidney expression of
YKL-40 was assessed by immunohistochemical staining using renal biopsy tissues from ANCA-associated
glomerulonephritis patients (AAGN). Severe AAV and FFS were defined as BVAS ≥ 12 and FFS ≥ 2, and the
correlations between laboratory variables, BVAS, FFS, and SF-36 score were assessed using linear regression analysis.
The optimal cut-off of serum YKL-40 for severe AAV and high FFS was calculated using the receiver operator
characteristic curve analysis.
Results: Of the included 60 patients, 32 (53.3%), 17 (28.3%), and 11 (18.3%) were classified as microscopic
polyangiitis, granulomatosis with polyangiitis, and eosinophilic granulomatosis with polyangiitis. The median BVAS
and FFS were 7.0 and 1.0, whereas the mean SF-36 physical and mental component scores were 50.5 and 58.3.
Serum YKL-40 level was higher in patients with severe AAV and high FFS compared to those without (p = 0.007 and
p < 0.001); multivariable linear regression analysis revealed that serum YKL-40 was independently associated with
BVAS, FFS, and SF-36 scores. On kidney tissues obtained from AAGN patients, strong cytoplasmic staining of YKL-40
was found in cells present in inflammatory lesions. In addition, AAV patients had higher levels of serum YKL-40
compared to those with systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis, and healthy control. The
proportion of patients having severe AAV and high FFS was significantly higher in those with serum YKL-40 > 221.3
(Continued on next page)
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: s.mcadoo@imperial.ac.uk; sangwonlee@yuhs.ac
†Sung Soo Ahn and Taejun Yoon are co-first authors.
5Centre for Inflammatory Disease, Department of Immunology and
Inflammation, Imperial College London, Hammersmith Campus, Du Cane
Road, London W120NN, UK
3Institute for Immunology and Immunological Diseases, Yonsei University
College of Medicine, Seoul, Republic of Korea
Full list of author information is available at the end of the article
Ahn et al. Arthritis Research & Therapy           (2021) 23:77 
https://doi.org/10.1186/s13075-021-02467-1
(Continued from previous page)
ng/mL and > 227.1 ng/mL than those without (relative risk 2.852 and 7.000). In 12 patients with serial YKL-40
testing, 11 patients (91.7%) exhibited a reduction in serum YKL-40 levels following a decrease in disease activity
(p < 0.001).
Conclusion: Our findings suggest that serum YKL-40 may be a clinically useful biomarker to assess AAV disease
activity.
Trial registration: Retrospectively registered.
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Background
Anti-neutrophil cytoplasmic autoantibody (ANCA)-asso-
ciated vasculitis (AAV) is a rare disease characterised by
necrotizing inflammation of predominantly small vessels
[1]. ANCAs against myeloperoxidase (MPO-ANCA) or
proteinase 3 (PR3-ANCA) are a serologic hallmark of
AAV, even though they are not detected in all AAV pa-
tients [2]. AAV is classified into three disease categories:
granulomatosis with polyangiitis (GPA), microscopic po-
lyangiitis (MPA), and eosinophilic GPA (EGPA) based
on clinical, laboratory, and pathological features [3]. In
recent decades, the clinical outcome of AAV has signifi-
cantly improved owing to advances in understanding of
the disease and to the advent of novel therapeutic ap-
proaches [4]. However, because disease activity not only
influences the choice of therapeutic regimens but also
predicts relapse or treatment-refractoriness during
follow-up, it is important to accurately determine the ac-
tivity of AAV [5]. Currently, several methods to assess
the disease activity of AAV have been proposed, such as
Birmingham vasculitis activity score (BVAS), physician
global assessment, disease extent index, and five factor
score (FFS) [6–8]. Although BVAS is the most widely
used index to determine AAV disease activity, the pres-
ence of observer variability and the complexity of BVAS
assessment makes it difficult to apply in clinical practice,
and an unmet need for a biomarker to assess disease ac-
tivity of AAV has been consistently raised [7].
Chitinase-3-like 1 protein (YKL-40) is a secreted
glycoprotein originally isolated from human osteosar-
coma cells [9]. YKL-40 is approximately 40 kDa in size
and is expressed and secreted by various cell types such
as neutrophils, macrophages, vascular smooth muscle
cells, chondrocytes, and synovial cells. Furthermore, it is
considered to be associated with inflammation and tissue
remodelling, and is increased in the sera of patients with
large vessel vasculitides of giant cell arteritis and
Takayasu arteritis [10–13]. In addition, previous studies
suggested that serum YKL-40 is elevated in those with
various medical conditions such as infections, auto-
immune diseases, and cancers [14]. On the other hand,
it was reported that elevated serum YKL-40 levels are as-
sociated with poor prognostic outcomes of various
cancers [15] and with disease activity in rheumatoid
arthritis (RA), psoriatic arthritis, and inflammatory
bowel diseases [16–18]. Particularly, serum YKL-40 has
been extensively studied in RA, and persistently in-
creased serum YKL-40 was also indicative of radiologic
disease progression [19]. Thus, serum YKL-40 is in-
cluded in the multi-biomarker disease activity score as
an objective measure to assess RA disease severity [20].
Because activated neutrophils and macrophages are im-
portant effector cells known to contribute to endothelial
and organ damages in AAV and are responsible for the
production of YKL-40 [1, 21], it can be speculated that
serum YKL-40 may be elevated in AAV. However, so
far, there has been no report on the clinical implications
of serum YKL-40 in AAV patients. Hence, in this study,
we investigated whether serum YKL-40 is associated
with AAV disease activity.
Methods
Patients
We selected 60 AAV patients who were enrolled in
the Severance Hospital ANCA-associated Vasculitides
(SHAVE) cohort from November 2016 to June 2018.
The SHAVE cohort is an observational cohort that
exclusively included AAV patients (MPA, GPA, and
EGPA), which was established in a major tertiary re-
ferral centre in South Korea. All patients were first
classified as AAV at the Department of Rheumatology
in Severance Hospital, fulfilled the 2007 European
Medicines Agency algorithms, and the 2012 Revised
International Chapel Hill Consensus Conference No-
menclature of Vasculitides [22, 23]. Serum samples
were collected and stored at diagnosis of AAV and
on every 3 month-visit day, when clinical and labora-
tory data were obtained. Particularly, on the visit day
of blood sampling, patients with serious medical con-
ditions other than AAV, such as cancers and infec-
tions, were excluded in this study. This study was
approved by the Institutional Review Board of Sever-
ance Hospital (4-2016-0901) and the patients’ written
informed consent was obtained at the time of blood
sampling.
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Clinical and laboratory data and blood sampling
Clinical data comprised of AAV classification, age, gen-
der, new onset AAV, disease duration, and clinical fea-
tures. We evaluated items of both BVAS and vasculitis
damage index (VDI) as clinical features. Perinuclear (P)-
ANCA and cytoplasmic (C)-ANCA were detected using
immunofluorescent assays, and MPO-ANCA and PR3-
ANCA were measured using ELISA kits for anti-MPO
and anti-PR3 (Thermo Fisher Scientific/Phadia, Freiburg,
Germany). For laboratory data, the results of white blood
cell, neutrophil, and platelet counts, erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP), cre-
atinine, aspartate aminotransferase, and alanine amino-
transferase (ALT) were collected. We also reviewed
immunosuppressive drugs administered on the day of
blood sampling using the Korean Drug Utilization Re-
view system. Whole blood was obtained from each AAV
patient and serum was isolated and stored at − 80 °C on
the same day of collecting clinical and laboratory data.
AAV-related parameters and definition of disease status
On the visit day of blood sampling, four categories of
AAV-related parameters were assessed: BVAS (version
3) as an index for the current AAV activity and severity
[7], FFS as a predictor of the prognosis of AAV [8], VDI
as an organ-based damage assessment [24], and the Ko-
rean version of the short form-36 (SF-36) [25] as an
index of physical and mental function. We defined pa-
tients as having severe AAV by stratifying AAV patients
into three groups according to the tertile of BVAS, and
the lower limit of the highest tertile was set as the cut-
off for severe AAV (BVAS ≥ 12). In addition, AAV pa-
tients with FFS ≥ 2 were defined as having high FFS [8].
Patients were classified as having new onset or persistent
disease when the disease duration was less than and over
1 month, respectively. The definition of active disease
and remission was set based on the European League
Against Rheumatism recommendations [26].
Serum YKL-40 measurement
Serum YKL-40 was measured using the stored serum
samples of 60 AAV patients. Serum samples of patients
with systemic lupus erythematosus (SLE) (n = 30), RA
(n = 28), osteoarthritis (OA) (n = 22), and healthy control
(HC) (n = 40) were used as controls. ELISA kits for
serum YKL-40 measurement were purchased from Qui-
del (CA, USA), and the levels of serum YKL-40 were
measured according to the manufacturer’s instructions.
Briefly, 20 μL of each serum sample was added to each
well and incubated with 100 μL of capture solution for
60 min at room temperature. After four washes with
washing buffer, 100 μL of enzyme conjugate was added
to each well. Again, the plate was covered with a plate
sealer and incubated for 60 min at room temperature.
The plate was then washed four times with washing buf-
fer. Next, 100 μL of substrate solution was added to each
well and the plate incubated for 60 min at room
temperature. Following this final period of incubation,
100 μL of stop solution (1 N sulphuric acid) was added
to each well and the OD value determined at 405 nm.
For external validation, the serum samples of patients
(n = 35) that were diagnosed as AAV at Imperial College
of London, the Centre for Inflammatory Diseases, were
used (application number 04/Q0406/25).
Immunohistochemical staining of kidney tissue
Immunohistochemistry was performed on formalin-fixed
paraffin-embedded kidney tissue obtained from patients
with non-proliferative glomerular disease (thin basement
membrane, n = 3; disease controls) and from ANCA-
associated glomerulonephritis (AAGN) (n = 5) provided
by the Imperial College NHS Trust Tissue Bank (appli-
cation number R15072), in accordance with local re-
search ethics committee approval. Following heat-
induced antigen retrieval, sections were incubated with
anti-YKL-40 primary antibody (Ab77528, Abcam, Cam-
bridge, UK) overnight at 4 °C, developed using an HRP-
conjugated secondary system (Vector Labs, Peterbor-
ough, UK) according to manufacturer’s instructions, and
counterstained with haematoxylin.
Statistical analysis
Distribution of normality in continuous data was evalu-
ated using Kolmogorov-Smirnov test, and continuous
variables were presented as mean with standard devi-
ation or median with interquartile range, as appropriate.
Differences of two continuous variables were compared
using the Student’s t-test and Mann-Whitney U test,
whereas Kruskal-Wallis test was conducted for compar-
ing two or more variables. Categorical variables are pre-
sented as frequencies and percentages. Correlations
between laboratory variables, BVAS, FFS, and SF-36
scores were assessed using univariable linear regression
analysis. Standardised correlation coefficients between
laboratory data, BVAS, FFS, and SF-36 scores were cal-
culated using multivariable linear regression analysis
with a forward entry method including variables that
showed statistical significance in univariable analysis.
The optimal cut-off of serum YKL-40 for severe AAV
and high FFS was calculated using the receiver operator
characteristic (ROC) curve analysis. Calculation of the
relative risk (RR) was performed using the contingency
tables and the chi-square test, and a paired t-test was
done to evaluate the changes of serum YKL-40 levels
after reduction of AAV activity. Statistical analyses were
performed using MedCalc statistical software version
18.6 (MedCalc Software, Ostend, Belgium) or GraphPad
Prism software version 5.0 (GraphPad Software, San
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Diego, CA, USA). A two-tailed p < 0.05 was considered
statistically significant.
Results
Baseline characteristics of patients with AAV
The baseline characteristics of AAV patients are shown
in Table 1. Thirty-two patients (53.3%) were classified as
MPA, 17 (28.3%) as GPA, and 11 (18.3%) as EGPA. The
mean age of the patients was 59.4 and 40 (66.7%) were
women. Twenty-three patients (38.3%) had new onset
AAV, and the median disease duration was 2.4 months.
For AAV-related parameters, the median BVAS, FFS,
and VDI scores were 7.0, 1.0, and 3.0, respectively. The
mean SF-36 physical component summary (PCS) and
mental component summary (MCS) scores were
assessed as 50.5 and 58.3, respectively. The most com-
mon clinical feature was pulmonary manifestation
(61.7%) followed by renal manifestation (55.0%). MPO-
ANCA (or P-ANCA) was detected in 37 patients (61.7%)
and PR3-ANCA (or C-ANCA) in seven patients (11.7%).
The median white blood cell and neutrophil counts,
ESR, CRP, and serum YKL-40 were 7345.0/mm3, 5000.0/
mm3, 30.0 mm/h, 1.4 mg/L, and 189.2 ng/mL, respect-
ively. Concerning immunosuppressive agents currently
being administered, glucocorticoids (70.0%) were the
most commonly used, followed by azathioprine (23.3%),
cyclophosphamide (13.3%), and tacrolimus (5.0%).
Serum YKL-40 levels according to disease activity and
ANCA positivity
We divided AAV patients into two subgroups based on
severe AAV and high FFS, and compared serum YKL-40
levels between patients with or without severe AAV or
high FFS. Patients with severe AAV exhibited higher
mean serum YKL-40 levels than those without (p =
0.007) (Fig. 1a). In addition, serum YKL-40 levels were
significantly elevated in patients with high FFS compared
to those without (p < 0.001) (Fig. 1b). Increased levels of
YKL-40 were also found in patients with active disease
compared to those in remission in sera provided from
an independent study population from the UK (p =
0.004) (Fig. 1c). Furthermore, when AAV patients were
assigned to three subgroups according to ANCA positiv-
ity, serum YKL-40 levels were significantly higher in pa-
tients with MPO-ANCA (or P-ANCA) than in those
without ANCAs (p = 0.003) (Fig. 1d).
Linear regression analyses of laboratory variables for
BVAS and FFS
In terms of the association between laboratory variables
and BVAS, white blood cell count, neutrophil count,
ESR, CRP, and serum YKL-40 were significantly corre-
lated with BVAS in univariable linear regression analysis.
In multivariable linear regression analysis, serum YKL-
40 (standardised β 0.301, 95% confidence interval [CI]
0.005, 0.035, p = 0.012) were significantly associated with
BVAS, together with CRP (standardised β 0.371, 95% CI
0.035, 0.153, p = 0.002) (Table 2). Regarding the associ-
ation between laboratory variables and FFS, CRP, cre-
atinine, ALT, and serum YKL-40 were significantly
correlated with FFS in univariable linear regression ana-
lysis. However, in multivariable linear regression ana-
lysis, serum YKL-40 (standardised β 0.476, 95% CI 0.002,
0.006, p < 0.001) was significantly associated with FFS,
together with creatinine (standardised β 0.329, 95% CI
0.055, 0.274, p = 0.004) (Table 2). The optimal cut-offs
of serum YKL-40 were calculated as 221.3 ng/mL for se-
vere AAV (area 0.710, 95% CI 0.578, 0.820; p = 0.003)
and 227.1 ng/mL for high FFS (area 0.870, 95% CI 0.759,
0.943; p < 0.001) using ROC analysis.
Linear regression analyses of laboratory variables for SF-
36 scores
We next evaluated the correlation between laboratory
variables and SF-36 scores. Univariable linear regression
analysis revealed that white blood cell, neutrophil, plate-
let counts, ESR, CRP, and serum YKL-40 were signifi-
cantly associated with SF-36 PCS score. In multivariable
analysis, serum YKL-40 (standardised β − 0.390, 95% CI
− 0.133, − 0.035, p = 0.001) and platelet count (standar-
dised β − 0.325, 95% CI − 0.125, − 0.022, p = 0.006) were
inversely associated with SF-36 PCS score. Similarly,
serum YKL-40 (standardised β − 0.297, 95% CI − 0.105,
− 0.010, p = 0.018), together with CRP (standardised β −
0.269, 95% CI − 0.385, − 0.018, p = 0.032), revealed to be
inversely correlated with SF-36 MCS score
(Additional file 1).
Serum YKL-40 levels and AAV classification, new onset
AAV, and items of BVAS
First, we compared serum YKL-40 among MPA, GPA,
and EGPA patients and found that serum YKL-40 levels
were significantly higher in patients with MPA and GPA
than in those with EGPA (Additional file 2a). In
addition, serum YKL-40 levels did not differ between pa-
tients with new onset and persistent MPA and EGPA,
whereas new onset GPA patients had higher serum
YKL-40 compared to those with persistent GPA (p =
0.019) (Additional file 2b). Regarding clinical features,
serum YKL-40 levels were significantly higher in AAV
patients with renal manifestation compared to those
with ear, nose, throat, pulmonary, and nervous system
manifestation (Additional file 2c).
Expression of YKL-40 in kidney tissue of AAV patients
Tissue expression of YKL-40 in AAV was examined
using renal biopsy material provided by the Imperial
College Tissue Bank. We first validated our
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immunohistochemical approach in lymph nodes, which
confirmed cytoplasmic expression of YKL-40 in a pro-
portion of cells within lymphoid follicles (likely mono-
cytes/macrophages) but not within the majority of
lymphocytes (Fig. 2a). In renal tissue taken from patients
with thin basement membrane disease, we found weak
cytoplasmic staining for YKL-40 in some renal tubular
epithelial cells, though minimal expression within the
glomerular tuft, consistent with previous descriptions of
YKL-40 expression in kidney tissue (Fig. 2b) [27]. In pa-
tients with AAGN, tubular expression of YKL-40 ap-
peared to be upregulated; in addition, strong
cytoplasmic staining was observed within inflammatory
lesions, including areas of glomerular extra-capillary
proliferation (Fig. 2c, d) and areas of tubulointerstitial
inflammation (Fig. 2e).
Comparison of serum YKL-40 levels in patients with AAV,
SLE, RA, OA, and HC
Because serum YKL-40 was previously reported to be ele-
vated in other autoimmune diseases and in OA [28, 29],
we compared serum YKL-40 among patients with AAV
and those with SLE, RA, OA, and HC. Serum YKL-40
level was higher in patients with AAV than those with
SLE, RA, and OA, as well as in those of HC (median YKL-
40: AAV 189.2 ng/mL vs. SLE 88.3 ng/mL vs. RA 73.7 ng/
mL vs. OA 87.4 ng/mL vs. mean YKL-40: HC 99.4 ng/
mL). In contrast, no difference in serum YKL-40 was
found among patients with SLE, RA, OA, and HC (Fig. 3).
RR of severe AAV and high FFS based on serum YKL-40
levels
Patients with serum YKL-40 > 221.3 ng/mL exhibited
a higher proportion of severe AAV than those with-
out (RR 2.852, 95% CI 1.269, 6.410, p = 0.011) (Add-
itional file 3a). In addition, high FFS was observed
more frequently in patients with serum YKL-40 >







Age, years 59.4 (14.3)
Female gender, n (%) 40 (66.7)
New onset AAV, n (%) 23 (38.3)
Disease duration, months† 2.4 (23.9)
AAV-related parameter
BVAS† 7.0 (10.5)
FFS (2009) † 1.0 (1.0)
VDI† 3.0 (2.0)
SF-36 PCS score 50.5 (22.4)
SF-36 MCS score 58.3 (20.1)
Clinical features (organ involvement), n (%)
General manifestation 17 (28.3)
Cutaneous manifestation 7 (11.7)
Mucous membrane and eye manifestation 3 (5.0)
Ear, nose, and throat manifestation 25 (41.7)
Pulmonary manifestation 37 (61.7)
Cardiovascular manifestation 3 (5.0)
Abdominal manifestation 1 (1.7)
Renal manifestation 33 (55.0)
Nervous system manifestation 12 (20.0)
ANCA positivity, n (%)
ANCA double positivity 1 (1.7)
MPO-ANCA (or P-ANCA) positivity 37 (61.7)
PR3-ANCA (or C-ANCA) positivity 7 (11.7)
ANCA negativity 17 (28.3)
Laboratory data
White blood cell count, /mm3† 7345.0 (5380.0)
Neutrophil count, /mm3† 5000.0 (4790.0)
Platelet count, × 1000/mm3† 254.0 (139.0)
ESR, mm/h† 30.0 (31.5)
CRP, mg/L† 1.4 (8.1)
Creatinine, mg/dL† 1.0 (1.4)
AST, IU/L† 18.0 (7.0)
ALT, IU/L† 18.5 (13.5)
Serum YKL-40, ng/mL† 189.2 (190.7)









Mycophenolate mofetil 2 (3.3)
Methotrexate 2 (3.3)
Values are expressed as mean (standard deviation) or in number (percentages)
†Continuous variables that were non-normally distributed are expressed as
median (interquartile range)
AAV ANCA-associated vasculitis, ANCA anti-neutrophil cytoplasmic antibody,
MPA microscopic polyangiitis, GPA granulomatosis with polyangiitis, EGPA
eosinophilic granulomatosis with polyangiitis, BVAS Birmingham vasculitis
activity score, FFS Five factor score, VDI Vasculitis damage index, SF-36 Short
form-36, PCS Physical component summary, MCS Mental component summary,
MPO myeloperoxidase, P perinuclear, PR3 proteinase 3, C cytoplasmic, ESR
erythrocyte sedimentation rate, CRP C-reactive protein, AST aspartate
aminotransferase, ALT alanine aminotransferase
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227.1 ng/mL than those without (RR 7.000, 95% CI
2.727, 17.972, p < 0.001) (Additional file 3b). On ap-
plying the cut-offs of serum YKL-40 for discriminat-
ing severe AAV and high FFS in AAV patients in
the UK cohort, patients with serum YKL-40 > 221.3
ng/mL and YKL-40 > 227.1 ng/mL showed a ten-
dency of higher risk of having severe AAV and high
FFS, even though statistical significance was not
found (RR 3.438, 95% CI 0.945, 12.505, p = 0.061 and
RR 9.120, 95% CI 0.578, 143.995, p = 0.116)
(Additional file 4a-b).
Changes in serum YKL-40 levels after reduction of AAV
activity
To further elucidate whether dynamic changes in serum
YKL-40 could reflect changes in AAV activity, we mea-
sured serum YKL-40 levels in patients with available
follow-up serum samples. Serial samples were obtainable
in 12 patients exhibiting a decrease in the follow-up
BVAS with an interval of 3 months or greater. Eleven of
12 patients (91.7%) exhibited a significant reduction in
serum YKL-40 after improvement of AAV (p < 0.001)
(Fig. 4).
Fig. 1 Serum YKL-40 levels in patients with severe AAV, high FFS, active disease, and ANCA positivity. Serum YKL-40 levels were significantly
higher in patients with a severe AAV and b high FFS compared to those without. c Serum YKL-40 was higher in patients with active disease
compared to those in remission from the UK samples. d MPO-ANCA (or P-ANCA)-positive AAV patients had significantly higher serum YKL-40
than those with ANCA negative patients. Data are shown as mean ± standard deviation or median (interquartile range), as appropriate.
Differences of two continuous variables were compared using the Student’s t-test and Mann-Whitney U test, whereas Kruskal-Wallis test was
conducted for comparing two or more variables. AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic antibody; FFS, Five factor
score; MPO, myeloperoxidase; P, perinuclear; PR3, proteinase 3; C, cytoplasmic
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Discussion
In clinical practice, acute phase reactants (i.e. ESR and
CRP) and ANCA titres are the most common laboratory
variables to assess current AAV activity. However, owing
to low specificity and reliability of these laboratory vari-
ables, a need for novel and convenient surrogate bio-
markers to assess and estimate the disease activity of
AAV has arisen [30, 31]. In this study, serum YKL-40
levels were significantly and independently associated
with both BVAS and FFS, and the levels of YKL-40 were
also higher in active disease samples provided from the
UK, which strongly supports our data. In addition, the
expression of YKL-40 was found to be increased in renal
biopsy samples of AAGN. Furthermore, patients with
serum YKL-40 levels > 221.3 ng/mL and > 227.1 ng/mL
exhibited significantly higher risks of severe AAV and
high FFS, respectively. It is also remarkable that serum
YKL-40 levels were significantly associated with both
SF-36 PCS and MCS scores, which is consistent with a
previous study that demonstrated that serum YKL-40 is
associated with the aggravation of functional disability in
RA [32]. Finally, serial measurement of serum YKL-40
levels reflected the changes of BVAS, indicating that
serum YKL-40 levels could be a potential biomarker for
assessing AAV disease activity.
The significant association between serum YKL-40
levels and the disease activity of AAV may be theoretic-
ally attributable to several reasons. First, YKL-40 can be
secreted by activated neutrophils as well as macro-
phages, which plays an important role in the pathogen-
esis of AAV [33]. Neutrophils, the majority of cells in
innate immunity, may induce organ injury in AAV by
acting both as effector cells responsible for tissue dam-
age and by promoting chemotaxis [34]. In addition, neu-
trophils may contribute to the formation of neutrophil
extracellular traps to perpetuate the inflammatory
process in AAV [35]. On the other hand, macrophages,
a likely cell type detected in AAGN biopsies, may accu-
mulate in the target tissues and provoke organ damage
in AAV at a response-to-injury phase following the reso-
lution of acute inflammation [21]. These immunological
aspects support the evidence that serum YKL-40 could
be a biomarker to assess the current AAV activity. Sec-
ond, serum YKL-40 can be secreted by endothelial cells
as a result of vessel damage. Interestingly, two previous
studies demonstrated that the levels of circulating mole-
cules indicating vascular injury and angiogenesis are in-
creased in AAV [36, 37]. Thus, it may be assumed that
serum YKL-40 levels increase when extensive vascular
damage and angiogenesis occurs. Alternatively, serum
Table 2 Linear regression analyses of laboratory variables for the current BVAS and FFS
Univariate analysis Multivariate analysis
Regression coefficient (crude B) Correlation coefficient (R = β) p-value Standardised β p-value
Laboratory variables vs. BVAS
White blood cell count 0.001 0.271 0.037
Neutrophil count 0.001 0.393 0.002
Platelet count 0.013 0.192 0.141
ESR 0.073 0.350 0.006
CRP 0.113 0.446 < 0.001 0.371 0.002
Creatinine 0.870 0.246 0.058
AST − 0.025 − 0.054 0.681
ALT 0.097 0.199 0.128
Serum YKL-40 0.026 0.393 0.002 0.301 0.012
Laboratory variables vs. FFS
White blood cell count 0.000 0.043 0.745
Neutrophil count 0.000 0.114 0.385
Platelet count − 0.001 − 0.109 0.406
ESR 0.006 0.195 0.136
CRP 0.010 0.270 0.037
Creatinine 0.284 0.567 < 0.001 0.329 0.004
AST 0.014 0.213 0.102
ALT 0.018 0.263 0.043
Serum YKL-40 0.006 0.641 < 0.001 0.476 < 0.001
BVAS Birmingham vasculitis activity score, FFS Five factor score, ESR Erythrocyte sedimentation rate, CRP C-reactive protein, AST aspartate aminotransferase, ALT
alanine aminotransferase
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YKL-40 may also be directly associated with inflamma-
tion in AAV by increasing chemotaxis, cellular attach-
ment, and vascular endothelial cell migration, resulting
in increased vascular injury [38]. The results from a pre-
vious study have shown that neutralisation of YKL-40
inhibits angiogenesis and progression in cancer cell lines,
and xenograft models support this hypothesis [39].
Third, serum YKL-40 levels may increase in AAV owing
to pro-inflammatory cytokines such as interleukin (IL)-6
and IL-17. Previous studies suggested that both IL-6 and
IL-17 are elevated in patients with AAV and could be
important cytokines in the pathogenesis of AAV [40].
Notably, a study by Berti et al. demonstrated that block-
ing of IL-6 leads to clinical efficacy in AAV patients
despite a relatively small number of patients [41], and
another study by Gan et al., which used animal models
of AAV, showed that IL-17A deficiency results in at-
tenuation of kidney injury [42]. Because both IL-6 and
IL-17A are known to enhance the expression of YKL-40
[43], it could be assumed that serum YKL-40 levels are
associated with disease activity in AAV.
On evaluating the expression of YKL-40 in the kidney
tissues of patients with thin basement membrane disease
and AAGN, we found that the expression of YKL-40
was prominent in AAGN tissues. The upregulation of
YKL-40 in the sera and kidneys in patients with AAV
suggests that YKL-40 could be a biomarker to evaluate
both generalised and localised inflammation in AAV. On
Fig. 2 Immunohistochemistry of YKL-40 in ANCA-associated glomerulonephritis. Immunohistochemistry was performed on kidney tissues
obtained from patients with non-proliferative glomerular disease (thin basement membrane, n = 3; disease controls) and from ANCA-associated
glomerulonephritis (n = 5). a Positive tissue control stain in lymph node (× 400). b Negative disease control staining in non-proliferative GN (thin
basement membrane lesion (× 200)). c, d YKL-40 staining in ANCA-associated glomerulonephritis, showing upregulation within tubular cells, and
expression within crescentic lesions (c × 200; d × 400 same glomerulus). e Tubulointerstitial infiltrate in active AAV (× 200). ANCA, Anti-neutrophil
cytoplasmic antibody; GN, Glomerulonephritis; AAV, ANCA-associated vasculitis
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the other hand, because it was also demonstrated that
the renal expression of YKL-40 increases during ische-
mic renal injury [44], it is also possible that YKL-40
could be a surrogate of organ injury, and further investi-
gations are necessary to verify the precise role of YKL-
40 in AAV.
In this study, a subgroup analysis revealed that serum
YKL-40 levels were significantly higher in patients with
MPO-ANCA (or P-ANCA) positivity compared to those
with ANCA negativity. In addition, serum YKL-40 levels
were significantly higher in patients with MPA and GPA
compared to EGPA, and in those with renal involvement
compared to those without. Although the relations be-
tween serum YKL-40 levels and AAV variants, ANCA
types, and involved organs are unclear, the presence of
MPO-ANCA (or P-ANCA) could be also relevant to this
observation, as a previous study discovered that sputum
YKL-40 is correlated with serum YKL-40, as well as spu-
tum MPO, vascular endothelial growth factor, IL-6, and
neutrophil count in patients with asthma [45]. The re-
sults that MPO-ANCA (or P-ANCA) positivity was the
most frequently detected in not only MPA patients, but
also in patients with renal vasculitis related to AAV may
support our assumption.
It is also noteworthy that the median serum YKL-40
levels in patients with AAV, SLE, RA, and OA were sig-
nificantly lower compared to AAV patients. The serum
titres of YKL-40 in RA and OA patients in this study
were similar to those of previous reports [28, 46]. A sig-
nificant difference in serum YKL-40 levels between AAV
and other diseases might be relevant to the extensive
vascular inflammation of the affected vessels in AAV,
which is associated with endothelial cell injury [21].
Therefore, these findings also stress the value of deter-
mining serum YKL-40 in AAV patients. However, al-
though serum YKL-40 level was also higher in AAV
patients compared to HC, there was no difference of its
level between SLE, RA, OA, and HC in our analysis.
Therefore, more studies are required to validate whether
serum YKL-40 may be useful in differentiating between
AAV, other autoimmune diseases, and HC.
Our study has two merits. To the best of our know-
ledge, this is the first study to evaluate the clinical sig-
nificance of serum YKL-40 levels in patients with AAV
and demonstrated that it could reflect disease activity in
AAV. In addition, the clinical and laboratory data in this
study were derived from a monocentric prospective co-
hort. We could thus prevent missing data, collect cross-
sectional clinical and laboratory data together with blood
samples, and minimise inter-centric variation. Moreover,
our results were found to be well replicated in an inde-
pendent cohort. However, our study also has several lim-
itations. First, a relatively small number of patients were
included, and despite the association between serum
Fig. 3 Serum YKL-40 levels in patients with AAV, SLE, RA, OA, and
HC. Patients with AAV exhibited significantly higher serum YKL-40
levels compared to those with SLE, RA, OA, and HC. Data are shown
as mean ± standard deviation or median (interquartile range), as
appropriate. Differences of two continuous variables were compared
using the Mann-Whitney U test, whereas Kruskal-Wallis test was
conducted for comparing two or more variables. AAV, ANCA-
associated vasculitis; ANCA, anti-neutrophil cytoplasmic antibody;
SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; OA,
osteoarthritis; HC, healthy control
Fig. 4 Changes in serum YKL-40 levels in patients with decreased
AAV activity. In 12 patients with serial YKL-40 measurement, serum
YKL-40 levels were significantly reduced with decreased BVAS at
follow-up. Paired t-test was done to evaluate the changes of serum
YKL-40 levels. AAV, ANCA-associated vasculitis; ANCA, Anti-neutrophil
cytoplasmic antibody; BVAS, Birmingham vasculitis activity score
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YKL-40 levels and FFS, the prognostic implication could
not be evaluated as the follow-up duration of the pa-
tients was not sufficiently long. Second, given that urin-
ary markers such as soluble 163 and monocyte
chemoattractant protein-1 have been recently proposed
to be a potential biomarker in AAV, the ideal method of
detecting YKL-40 (either in the blood, urine, or tissue)
to provide optimal clinical information remains unclear.
Third, the optimal cut-offs of serum YKL-40 that were
proposed in our study could not be fully validated in an
independent cohort. Fourth, we were not able to identify
cell types expressing YKL-40, or determine whether
YKL-40 has a functional role in AAV (regarding patho-
genesis or in modulating the response to injury) in this
study. Additional studies are warranted to validate our
results and provide better insights concerning the role of
YKL-40 in AAV.
Conclusions
We demonstrated that serum YKL-40 levels are signifi-
cantly associated with disease activity in AAV and are
upregulated in kidney tissues of AAGN. In addition,
serum YKL-40 levels decreased following reduction of
disease activity. Therefore, our results suggest that meas-
uring serum YKL-40 levels could provide useful infor-
mation in assessing AAV disease activity.
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